TNFSF14 and neoplasm: Targeting LIGHT in treatment not only recruits naive T cells but also selectively expands tumor antigen-specific T cells within tumor tissues, thereby fostering a T cell-inflamed microenvironment and overcoming tumor resistance to checkpoint blockade therapy (107–109).